RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.18
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$31.65

24 Jul
2024

0.430

OPEN

$31.22

1.38%

HIGH

$31.65

1,771,311

LOW

$31.06

TARGET
$33.342

+0.11 change from previous day

 5.3% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) 118.9 xxx
DPS (cps) 30.1 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 26.3 xxx
Dividend Yield 1.0% xxx
Div Pay Ratio(%) 25.4% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.78%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.88

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/05 - ex-div 5.15c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx90.9
DPS All xxxxxxxxxxxxxxx21.9
Sales/Revenue xxxxxxxxxxxxxxx6,278.2 M
Book Value Per Share xxxxxxxxxxxxxxx421.9
Net Operating Cash Flow xxxxxxxxxxxxxxx1,030.7 M
Net Profit Margin xxxxxxxxxxxxxxx21.25 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx24.06 %
Return on Invested Capital xxxxxxxxxxxxxxx18.15 %
Return on Assets xxxxxxxxxxxxxxx15.20 %
Return on Equity xxxxxxxxxxxxxxx24.06 %
Return on Total Capital xxxxxxxxxxxxxxx23.14 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx468.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx48 M
Long Term Debt xxxxxxxxxxxxxxx2,326 M
Total Debt xxxxxxxxxxxxxxx2,373 M
Goodwill - Gross xxxxxxxxxxxxxxx4,162 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx342 M
Price To Book Value xxxxxxxxxxxxxxx7.78

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx199.2 M
Capex % of Sales xxxxxxxxxxxxxxx3.17 %
Cost of Goods Sold xxxxxxxxxxxxxxx2,839 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,727 M
Research & Development xxxxxxxxxxxxxxx428 M
Investments - Total xxxxxxxxxxxxxxx221 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.7

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

24/06/2024

1

Overweight

$33.70

6.48%

More detailed results have been released from Eli Lilly's P3 Surmount OSA study evaluating tirzepatide for treatment of moderate/severe obstructive sleep apnea (OSA).

Key new details are the secondary outcomes as it relates to "disease resolution", explains Morgan Stanley.

Study 1 (no PAP therapy) and Study 2 (PAP therapy) showed that 43.0% and 51.5% of participants, respectively, treated with tirzepatide at the highest dose met the criteria for "disease resolution".

This data places more emphasis on the ultimate validation of the "funnel argument", notes Morgan Stanley, in order for the GLP1 category to not impact the total addressable market (TAM) for continuous positive airway pressure (CPAP) machines.

Overweight rating. Target $33.70. Industry View: In-Line.

FORECAST
Morgan Stanley forecasts a full year FY24 dividend of 29.29 cents and EPS of 115.92 cents.
Morgan Stanley forecasts a full year FY25 dividend of 29.29 cents and EPS of 131.18 cents.

UBS

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

3

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Wilsons

03/05/2024

1

Overweight

$36.00

13.74%

Wilsons analysts maintain their Overweight rating on ResMed, upgrading the price target by 9% to $36, citing significant gross margin expansion as a key driver.

The broker reports 3Q revenue of US$1,197m, a 7% increase year-on-year, was 2% above forecasts, driven by robust sales in both US and Rest of World (ROW) markets.

The report highlights ResMed's gross margin improved by 260 basis points due to efficiencies such as freight cost reductions and inventory management, with further enhancements anticipated.

EPS forecasts for FY24 through FY26 have been raised by 3-5% based on higher device sales and earlier gross margin improvements.

FORECAST
Wilsons forecasts a full year FY24 dividend of 29.59 cents and EPS of 117.75 cents.
Wilsons forecasts a full year FY25 dividend of 32.03 cents and EPS of 134.99 cents.

Goldman Sachs

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

RMD STOCK CHART

FNArena News on RMD

1
Rudi’s View: How To Invest Allan’s $300k, Part 2

Jul 25 2024 - Rudi's View
2
Rudi’s View: Rate Cuts, Growth & Small Caps

Jul 18 2024 - Rudi's View
3
Rudi’s View: Gold, Healthcare, Staples & Copper

Jul 11 2024 - Rudi's View
4
Rudi’s View: All-Weather Portfolio in FY24; Growth Not Value

Jul 10 2024 - Rudi's View
5
Rudi’s View: Met Coal, Banks, GenAi & Buying-The-Dip

Jul 04 2024 - Rudi's View

Latest Medical Equipment & Devices News

1
Rudi’s View: How To Invest Allan’s $300k, Part 2

Jul 25 2024 - Rudi's View
2
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps
3
ResMed Silences The Doubters

Apr 29 2024 - Australia
4
Dr Boreham’s Crucible: 4D Medical

Apr 23 2024 - Small Caps
5
Uptrend Resumed For ResMed

Mar 19 2024 - Technicals
6
Dr Boreham’s Crucible: Cochlear

Feb 28 2024 - Australia
7
Rudi Interviewed: Ongoing Potential In Technology & Growth

Feb 19 2024 - Rudi's View
8
Dr Boreham’s Crucible: Artrya

Feb 15 2024 - Small Caps
9
ResMed Recovery Turns Into Hollywood Script

Jan 31 2024 - Australia
10
ResMed Makes A Comeback

Jan 29 2024 - Australia